百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

交易中 07-10 14:14:09

185.500

+3.600

+1.98%

最高188.000	最低180.400	成交量275.86万
今开182.200	昨收181.900	日振幅4.18%
总市值2,859亿	流通市值2,645亿	总股本15.41亿
成交额5.09亿	换手率0.19%	流通股本14.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":185.5,"timestamp":1783664038353,"preClose":181.9,"halted":0,"volume":2758611,"delay":0,"changeRate":0.019791094007696505,"floatShares":1426000000,"shares":1541000000,"eps":1.4893433563528333,"marketStatus":"交易中","change":3.6,"latestTime":"07-10 14:14:09","open":182.2,"high":188,"low":180.4,"amount":509484584,"amplitude":0.041781,"askPrice":185.6,"askSize":1300,"bidPrice":185.5,"bidSize":3200,"shortable":3,"etf":0,"ttmEps":2.6555619135710535,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1783671000000},"marketStatusCode":2,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":181.9,"openAndCloseTimeList":[[1783647000000,1783656000000],[1783659600000,1783670400000]],"volumeRatio":0.70274,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"BOM.HK","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":265.88,"timestamp":1783664048000,"preClose":260.78,"halted":0,"volume":6123100,"delay":0,"premium":"-39.63"},"impliedVol":0.4475,"impliedVolPercentile":0.8522},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"1199609039","title":"异动解读｜百济神州盘中上涨3.19%，生物科技板块强势联动叠加百悦泽临床数据持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1199609039","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199609039?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:17","pubTimestamp":1783653455,"startTime":"0","endTime":"0","summary":"7月10日，百济神州盘中上涨3.19%，报187.7港元/股，成交额3.67亿港元。此外，公司核心产品百悦泽在套细胞淋巴瘤一线治疗的MANGROVE 3期临床研究此前达到主要终点，无化疗方案使疾病进展或死亡风险降低43%，公司计划下半年进行全球注册申报，积极数据持续催化。同时，华福证券近日首次覆盖百济神州并给予\"买入\"评级，目标价297.44港元，认为公司已迈入多曲线增长新纪元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123809732","title":"百济神州（06160）授出33,388股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=1123809732","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123809732?lang=zh_cn&edition=full","pubTime":"2026-07-08 17:07","pubTimestamp":1783501640,"startTime":"0","endTime":"0","summary":"2026年7月8日，百济神州有限公司公告称，公司董事会薪酬委员会已于2026年7月2日根据“2016期权及激励计划”向215名承授人授出共计33,388股美国存托股份的受限制股份单位，相当于434,044股普通股，占公告当日公司已发行股份总数的0.03%。\\n4. 授出当日每股ADS收市价：297.65美元。\\n    在特定控制权变更或终止事件发生时，部分RSU可加速归属。\\n6. 退扣机制：本次授出RSU未附带可供公司收回的退扣机制，但须符合公司根据激励计划就税务扣缴的相关规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649610229","title":"百济神州(06160.HK)授出合共3.34万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2649610229","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649610229?lang=zh_cn&edition=full","pubTime":"2026-07-08 17:02","pubTimestamp":1783501342,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","LU0307460666.USD","LU1303224171.USD","LU1251922891.USD","LU1969619763.USD","06160","BK1161","LU1719994722.HKD","LU1770034418.SGD","LU2328871848.SGD","BK1588","BK1500","KURE","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649020961","title":"百济神州(06160)授出合共3.34万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2649020961","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649020961?lang=zh_cn&edition=full","pubTime":"2026-07-08 17:02","pubTimestamp":1783501342,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年7月2日，董事会薪酬委员会根据2016期权及激励计划的条款授予215名承授人合共3.34万股美国存托股份受限制股份单位。该等受限制股份单位相当于43.4万股股份，约占本公告之日公司发行股份总数的0.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KURE","06160","BK4588","BK1583","LU0307460666.USD","BK1500","LU2328871848.SGD","LU1770034418.SGD","BK1588","LU1969619763.USD","BK4585","BK1161","BK0239","BK4526","LU1719994722.HKD","688235","ONC","LU0588546209.SGD","BK4139","LU1303224171.USD","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170826936","title":"百济神州更新2026年6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1170826936","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170826936?lang=zh_cn&edition=full","pubTime":"2026-07-08 06:13","pubTimestamp":1783462398,"startTime":"0","endTime":"0","summary":"百济神州于2026年7月8日公布了截至2026年6月30日的证券变动月报表。报告显示，公司已发行普通股数量保持在1,426,363,848股，未有新增发行、购回或注销活动。此外，公司于上海证券交易所科创板上市的人民币股份数量同样维持在115,055,260股。根据公告，百济神州的法定/注册股本上月底与本月底均为2,311,463,847股，每股面值为0.0001美元，注册股本总额为231,146.38美元。截至2026年6月底，公司股本维持稳定，日常合规要求得到满足。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649607506","title":"百济神州：截至2026年3月31日股东户数为35,393户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649607506","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649607506?lang=zh_cn&edition=full","pubTime":"2026-07-07 15:36","pubTimestamp":1783409766,"startTime":"0","endTime":"0","summary":"证券之星消息，百济神州07月07日在投资者关系平台上答复投资者关心的问题。请问截止6月18日，公司A股的股东人数是多少，谢谢！公司在已披露的2026年第一季度报告中公布，截至2026年3月31日，公司普通股的登记股东有35,385户和8户美国存托股份的记录持有人，合计35,393户。公司会在定期报告中面向所有投资者统一披露截至相应报告期末的股东户数，敬请关注公司定期报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700020780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1770034418.SGD","LU1251922891.USD","BK0239","BK1161","BK1500","688235","KURE","LU0588546209.SGD","LU1719994722.HKD","LU1303224171.USD","LU2328871848.SGD","LU0307460666.USD","BK1588","LU1969619763.USD","06160","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649607885","title":"【券商聚焦】华福证券首予百济神州(06160)“买入”评级 指公司迈入多曲线增长新纪元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649607885","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649607885?lang=zh_cn&edition=full","pubTime":"2026-07-07 15:25","pubTimestamp":1783409101,"startTime":"0","endTime":"0","summary":"实体瘤领域被视为公司的第二增长曲线，多款产品进入关键临床。首次覆盖，给予“买入”评级，目标价297.44港元，认为公司已迈入多曲线增长新纪元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985267","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","ONC","161027","688235","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183818167","title":"异动解读｜百济神州盘中下跌3.1%，报184.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183818167","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183818167?lang=zh_cn&edition=full","pubTime":"2026-07-07 14:02","pubTimestamp":1783404144,"startTime":"0","endTime":"0","summary":"7月7日，百济神州盘中下跌3.1%，报184.6港元/股，成交额6.26亿港元。百济神州所在的生物科技行业中，板块整体承压，个股中，康方生物跌4.47%，信达生物跌3.65%，科伦博泰生物跌2.39%，三生制药跌5.4%，荣昌生物跌6.26%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649714608","title":"刘建出任广药集团战略科学家","url":"https://stock-news.laohu8.com/highlight/detail?id=2649714608","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649714608?lang=zh_cn&edition=full","pubTime":"2026-07-07 09:46","pubTimestamp":1783388760,"startTime":"0","endTime":"0","summary":"新京报讯从百济神州离任后，刘建找到了新东家。7月6日，广药集团宣布，刘建加盟广药集团，出任广药集团战略科学家。加入广药集团前，刘建任百济神州全球执委会委员、创新中心首席执行官及生物药业董事长。在任期间，刘建领导了百济神州创新中心的创新药物孵化业务及百济神州广州生物药生产基地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607073796142441.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607073796142441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1588","LU2328871848.SGD","LU1969619763.USD","BK1583","LU0307460666.USD","LU1303224171.USD","KURE","LU0588546209.SGD","LU1719994722.HKD","06160","BK1500","BK1161","LU1770034418.SGD","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649644557","title":"研报掘金丨华福证券：首予百济神州“买入”评级，迈入多曲线增长新纪元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649644557","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649644557?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:53","pubTimestamp":1783324417,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1969619763.USD","KURE","BK1161","LU1770034418.SGD","BK1500","LU0588546209.SGD","LU1303224171.USD","BK1588","LU1251922891.USD","LU2328871848.SGD","BK1583","LU0307460666.USD","LU1719994722.HKD","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154670562","title":"异动解读｜百济神州盘中上涨3.17%，百悦泽三期临床积极数据持续催化叠加板块联动","url":"https://stock-news.laohu8.com/highlight/detail?id=1154670562","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154670562?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:06","pubTimestamp":1783303582,"startTime":"0","endTime":"0","summary":"7月6日，百济神州盘中上涨3.17%，报189.4港元，成交额2.27亿港元。消息面上，百悦泽（泽布替尼）在套细胞淋巴瘤一线治疗的MANGROVE 3期临床研究达到主要终点，无化疗方案较标准免疫化疗方案使疾病进展或死亡风险降低43%（HR=0.57），公司计划下半年进行全球注册申报，积极数据持续催化股价上行。同时，生物科技板块今日整体走强，信达生物涨6.38%、荣昌生物涨6.38%、科伦博泰生物涨5.81%、三生制药涨4.35%、康方生物涨3.91%，板块联动为股价提供支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649691717","title":"每周股票复盘：百济神州（688235）百悦泽临床研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2649691717","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649691717?lang=zh_cn&edition=full","pubTime":"2026-07-05 01:22","pubTimestamp":1783185731,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，百济神州报收于266.96元，较上周的232.1元上涨15.02%。本周，百济神州7月2日盘中最高价报268.88元。百济神州当前最新总市值4114.97亿元，在化学制药板块市值排名1/149，在两市A股市值排名34/5203。本周关注点公司公告汇总：百悦泽在套细胞淋巴瘤一线治疗3期临床研究MANGROVE达到主要终点PFS。公司公告汇总百济神州有限公司自愿披露其产品百悦泽在套细胞淋巴瘤成人初治患者一线治疗中的3期临床研究MANGROVE取得积极结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","LU0307460666.USD","LU1719994722.HKD","BK0239","KURE","BK1588","LU0588546209.SGD","LU2328871848.SGD","06160","LU1251922891.USD","BK1500","BK1161","688235","LU1770034418.SGD","BK1583","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110023143","title":"异动解读｜百济神州盘中上涨3.49%，百悦泽三期临床积极数据持续催化叠加板块联动","url":"https://stock-news.laohu8.com/highlight/detail?id=1110023143","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110023143?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:42","pubTimestamp":1783042932,"startTime":"0","endTime":"0","summary":"7月3日，百济神州盘中上涨3.49%，报181.6港元，成交额1.15亿港元。生物科技板块今日延续强势，三生制药涨5.24%、荣昌生物涨5.5%、科伦博泰生物涨3.89%、康方生物涨3.32%、信达生物涨2.99%，板块联动为股价上行提供支撑。此外，医保目录初审通过率达92%叠加商保创新药目录机制落地，创新药支付端政策持续优化，行业情绪回暖。此前4.46亿元补税利空已基本消化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648632139","title":"港股异动 | 百济神州(06160.HK)早盘涨超4% MANGROVE 3期临床研究取得积极结果 计划下半年进行申报","url":"https://stock-news.laohu8.com/highlight/detail?id=2648632139","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648632139?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:36","pubTimestamp":1783042590,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1719994722.HKD","LU2328871848.SGD","BK1161","06160","LU0307460666.USD","LU1303224171.USD","LU1770034418.SGD","LU0588546209.SGD","BK1588","LU1969619763.USD","BK1583","LU1251922891.USD","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648321346","title":"港股异动 | 百济神州(06160)早盘涨超4% MANGROVE 3期临床研究取得积极结果 计划下半年进行申报","url":"https://stock-news.laohu8.com/highlight/detail?id=2648321346","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648321346?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:36","pubTimestamp":1783042590,"startTime":"0","endTime":"0","summary":"消息面上，近日，百济神州发布公告，MANGROVE 3期临床研究取得积极结果。MANGROVE是首个在该治疗场景下评估基于BTK抑制剂的无化疗方案对比标准免疫化疗方案的全球性、随机3期临床研究。该关键性3期临床研究的积极结果有望巩固泽布替尼在MCL疾病领域中的临床证据基础。百济神州计划在即将召开的医学大会上公布MANGROVE研究的完整结果，并正与全球监管机构就相关注册申报计划开展沟通，计划于2026年下半年进行申报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","LU1770034418.SGD","LU1251922891.USD","06160","VXUS","BK1500","688235","BK1161","BK1588","BK4585","BK4139","ONC","BK4526","LU1969619763.USD","BK4588","LU0307460666.USD","LU0588546209.SGD","LU1303224171.USD","BK1583","BK0239","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634520","title":"【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634520","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634520?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:36","pubTimestamp":1783038993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研究指，2026年6月29日，国家医保局公示通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单及相关信息。叠加今年首次引入的“预申报”机制，本次结果充分体现了医保目录调整对创新药的持续倾斜，看好相关创新药及制药企业的医保准入与商保增量空间。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518931.SGD","LU1961090484.USD","LU1226287792.SGD","LU0502904849.HKD","IE00B031HY20.USD","LU2097828631.EUR","HK0000165453.HKD","01093","LU0067412154.USD","LU2039709279.SGD","02616","01877","LU0417516738.SGD","01477","LU0856984785.SGD","LU2488822045.USD","LU0456846285.SGD","LU1226287875.USD","IE0008369823.USD","LU2097828714.EUR","LU0348766576.USD","LU2476274308.USD","LU2778985437.USD","LU0043850808.USD","LU0417516902.SGD","159992","LU0501845795.SGD","01177","06978","09926","LU2476274720.SGD","06185","LU1688375341.USD","01801","LU1969619763.USD","LU2097828805.USD","LU3063872942.SGD","LU0979878070.USD","LU0315179316.USD","SG9999004220.SGD","BK1589","06160","IE00B5MMRT66.SGD","09688","LU0072913022.USD","09995","601066","02269","02142","LU0516422366.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167435147","title":"异动解读｜百济神州盘中上涨3.35%，百悦泽三期临床积极结果叠加板块联动推升股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1167435147","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167435147?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:20","pubTimestamp":1782958809,"startTime":"0","endTime":"0","summary":"7月2日，百济神州盘中上涨3.35%，报174.7港元，成交额5.26亿港元。与此同时，生物科技板块今日集体走强，三生制药涨9.65%、康方生物涨7.67%、科伦博泰生物涨7.38%、信达生物涨6.6%，板块联动为股价反弹提供支撑。此前因4.46亿元补税事项导致的短期利空已基本消化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648522977","title":"智通港股早知道 | 当前美国通胀水平仍然过高 港股通入通门槛或已升至市值102.67亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2648522977","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648522977?lang=zh_cn&edition=full","pubTime":"2026-07-02 07:13","pubTimestamp":1782947606,"startTime":"0","endTime":"0","summary":"港股通入通门槛或已升至市值102.67亿智通财经APP获悉，随着2026年上半年结束，备受投资者关注的恒指季检和港股通调整，也成为市场关注的话题。当前港股通纳入门槛可能已升至约102.67亿，剔除门槛达约66.89亿港元。由截至2025年3月31日止年度的亏损净额转为截至2026年3月31日止年度的溢利净额，主要由于年内确认债务重组收益6.53亿港元所致。截至收盘，暗盘交易显示报价95.5港元，较招股价99.32港元下跌3.85%，每手100股，不计手续费，每手亏382港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","02866","BK1179","06160","BK4588","LU1251922891.USD","LU1770034418.SGD","LU1303224171.USD","VXUS","02476","BK1170","BK1172","LU1719994722.HKD","02282","BK1161","LU1481107354.HKD","BK1124","BK1535","LU2328871848.SGD","BK1588","LU0149721374.USD","BK1500","03337","BK1583","BK1202","00327","LU0307460666.USD","LU0588546209.SGD","LU0164880469.USD","BK4585","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648559726","title":"百济神州补税风波：刚“摘U”即遇4.46亿元追缴，逾20家药企卷入，医药合规进入刚性时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2648559726","media":"华夏时报网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648559726?lang=zh_cn&edition=full","pubTime":"2026-07-01 13:52","pubTimestamp":1782885155,"startTime":"0","endTime":"0","summary":"4.46亿元补税计入2026年损益，刚刚扭亏为盈的百济神州，正在为一场突如其来的补税“埋单”。2026年6月27日，百济神州一纸公告引发关注：公司一家境内全资子公司需补缴税款及滞纳金合计约4.46亿元。而就在不久前，这家创新药龙头刚刚摘掉“未盈利”的标签，首次实现年度盈利，并上调全年业绩指引。但百济神州并非个案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607013790080574.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607013790080574.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","688235","BK1583","BK1574","LU0588546209.SGD","BK4526","BK4139","LU1770034418.SGD","BK1500","06160","LU1251922891.USD","09939","BK1588","LU0307460666.USD","LU1719994722.HKD","159938","LU2328871848.SGD","BK1515","ONC","LU1969619763.USD","BK4588","BK0239","BK4585","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647551019","title":"百济神州最新公告：公司产品百悦泽3期临床研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2647551019","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647551019?lang=zh_cn&edition=full","pubTime":"2026-06-30 21:50","pubTimestamp":1782827419,"startTime":"0","endTime":"0","summary":"百济神州(688235.SH)公告称，公司产品百悦泽(泽布替尼胶囊)的3期临床研究MANGROVE取得积极结果。该研究评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗(BR)用于套细胞淋巴瘤(MCL)成人初治患者一线治疗。研究达到主要终点无进展生存期(PFS)，相较BR方案，百悦泽联合利妥昔单抗使疾病进展或死亡风险降低43%(HR=0.57)。公司计划于2026年下半年进行申报。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000045999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1588","BK1583","LU0588546209.SGD","BK1161","LU0307460666.USD","BK0239","688235","LU1303224171.USD","LU1770034418.SGD","BK1500","LU1969619763.USD","LU2328871848.SGD","06160","LU1719994722.HKD","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":0.139},{"period":"3month","weight":-0.0381},{"period":"6month","weight":-0.0781},{"period":"1year","weight":0.2094},{"period":"ytd","weight":0.0145}],"compareEarnings":[{"period":"1week","weight":0.0423},{"period":"1month","weight":-0.0218},{"period":"3month","weight":-0.072},{"period":"6month","weight":-0.0839},{"period":"1year","weight":0.0058},{"period":"ytd","weight":-0.0624}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeOne Medicines AG（原名：BeiGene Ltd）是一家全球肿瘤学公司，致力于为全球癌症患者研发新疗法。该公司产品组合涵盖血液学和实体瘤，致力于开发多样化的新型疗法。其产品包Brukinsa、Tevimbra和Pamiparib。Brukinsa是一种口服的布鲁顿酪氨酸激酶(BTK)小分子抑制剂。Tevimbra是一种人源化免疫球蛋白G4（IgG4）抗程序性细胞死亡蛋白1（PD-1）单克隆抗体，具有高亲和力和对PD-1的结合特异性。Tevimbra旨在最大限度地减少与巨噬细胞上Fc-γ（Fcy）受体的结合，帮助人体免疫细胞检测和对抗肿瘤。该公司正在开发的产品线包括Sonrotoclax、Tarlatamab、Zanidatamab、Blinatumomab、BGB-26808、BGB-R046、BG-68501、BG-C9074、BGB-43395、Xaluritamig等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.027621},{"month":2,"riseRate":0.5,"avgChangeRate":0.032126},{"month":3,"riseRate":0.125,"avgChangeRate":-0.059409},{"month":4,"riseRate":0.5,"avgChangeRate":0.034277},{"month":5,"riseRate":0.375,"avgChangeRate":-0.043816},{"month":6,"riseRate":0.375,"avgChangeRate":0.001624},{"month":7,"riseRate":0.875,"avgChangeRate":0.093405},{"month":8,"riseRate":0.857143,"avgChangeRate":0.058603},{"month":9,"riseRate":0.5,"avgChangeRate":0.025162},{"month":10,"riseRate":0.5,"avgChangeRate":-0.027038},{"month":11,"riseRate":0.625,"avgChangeRate":0.118183},{"month":12,"riseRate":0.125,"avgChangeRate":-0.07577}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}